Leptomeningeal metastases (LM) are a devastating complication of HER2 + metastatic breast cancer (MBC), with no effective treatments. In a case series of 8 patients with heavily pretreated HER2 + MBC and progressing LM, all 8 patients (100%) derived clinical benefit from Trastuzumab deruxtecan (TDXd), and 4 patients (50%) had an objective partial response based on formal neuroradiology MRI reads using the EORTC/RANO-LM Revised-Scorecard. T-DXd warrants further study in LM in HER2 + MBC and solid tumors where T-DXd may be active.
Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan / L. Alder, D. Trapani, C. Bradbury, A.E.D. Van Swearingen, S.M. Tolaney, M. Khasraw, C.K. Anders, C.D. Lascola, L. Hsu, N.U. Lin, S. Sammons. - In: NPJ BREAST CANCER. - ISSN 2374-4677. - 9:1(2023), pp. 19.1-19.5. [10.1038/s41523-023-00519-0]
Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan
D. TrapaniSecondo
Conceptualization
;
2023
Abstract
Leptomeningeal metastases (LM) are a devastating complication of HER2 + metastatic breast cancer (MBC), with no effective treatments. In a case series of 8 patients with heavily pretreated HER2 + MBC and progressing LM, all 8 patients (100%) derived clinical benefit from Trastuzumab deruxtecan (TDXd), and 4 patients (50%) had an objective partial response based on formal neuroradiology MRI reads using the EORTC/RANO-LM Revised-Scorecard. T-DXd warrants further study in LM in HER2 + MBC and solid tumors where T-DXd may be active.
| File | Dimensione | Formato | |
|---|---|---|---|
|
s41523-023-00519-0.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
2.61 MB
Formato
Adobe PDF
|
2.61 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
